Table 3.
Characteristics of clinical trials and drugs on TAM-targeted therapy stratified by targeting mechanisms
| Targeting pathways and mechanisms | Trials, N | Drugs, N | Active drugs | Trial status | Combination therapy |
|---|---|---|---|---|---|
| CSF-1/CSF-1R | 58 | 20 | ABSK-021 | I | monotherapy |
| AMB-051 | II | PD-1 | |||
| ARRY-382 | II | PD-1 | |||
| SNDX-6532 | II | monotherapy | |||
| chiauranib | III | chemotherapy | |||
| NMS-03592088 | II | monotherapy | |||
| pamufetinib | III | monotherapy | |||
| pexidartinib | launched | chemotherapy, radiotherapy, PD-1, targeted drugs | |||
| Q702 | I | PD-1 | |||
| surufatinib | launched | chemotherapy | |||
| TPX-0022 | I | monotherapy | |||
| vorolanib | III | monotherapy | |||
| CCL2/CCR2 | 14 | 5 | BMS-813160 | II | PD-1, chemotherapy, vaccination |
| CCX-872 | II | chemotherapy, radiotherapy | |||
| CCL5/CCR5 | 10 | 4 | maraviroc | I | PD-1, chemotherapy |
| leronlimab | II | chemotherapy | |||
| OB-002 | I | monotherapy | |||
| vicriviroc | II | PD-1 | |||
| CXCL12/CXCR4 | 115 | 15 | balixafortide | III | chemotherapy |
| burixafor | II | chemotherapy | |||
| GMI-1359 | I | monotherapy | |||
| mavorixafor | III | targeted inhibitor | |||
| motixafortide | III | chemotherapy, PD-1, PD-L1, targeted inhibitor | |||
| CD40/CD40L | 65 | 16 | ABBV-368 | I | PD-1, chemotherapy |
| ABBV-927 | II | PD-1, chemotherapy | |||
| CDX-1140 | I | radiotherapy, vaccination | |||
| GEN-1042 | II | monotherapy | |||
| mitazalimab | I | chemotherapy | |||
| NG-350A | I | monotherapy | |||
| selicrelumab | I | PD-1, CTLA-4, chemotherapy, vaccination | |||
| SL-172154 | I | monotherapy | |||
| sotigalimab | II | PD-1, chemotherapy, radiotherapy, vaccination | |||
| YH-003 | II | PD-1, chemotherapy | |||
| TLRs | 175 | 37 | |||
| TLR7 | AL-034 | II | targeted inhibitor | ||
| BDB-001 | I | PD-1, PD-L1 | |||
| BDC-1001 | II | PD-1 | |||
| BNT-411 | II | PD-L1, chemotherapy | |||
| DSP-0509 | II | PD-1 | |||
| RG-6115 | I | monotherapy | |||
| imiquimod | II | monotherapy | |||
| MBS-8 | I | monotherapy | |||
| resiquimod | II | PD-1, vaccination | |||
| TLR8 | DNA1 | I | monotherapy | ||
| SBT-6050 | I | PD-1 | |||
| DN-1508052 | I | monotherapy | |||
| motolimod | II | PD-1, chemotherapy, radiotherapy, targeted drugs | |||
| TLR9 | AST008 | II | monotherapy | ||
| CMP-001 | III | PD-1 | |||
| tilsotolimod | III | PD-1, CTLA4 | |||
| SD-101 | II | PD-1, radiotherapy | |||
| cavrotolimod | II | PD-1 | |||
| lefitolimod | III | CTLA4, chemotherapy | |||
| TLR5 | MRx-518 | II | radiotherapy | ||
| TLR3 | poly-ICLC | III | PD-1, vaccination, chemotherapy, radiotherapy | ||
| rintatolimod | launched | PD-1, vaccination, chemotherapy | |||
| PI3Kγ signal pathway | 90 | 12 | copanlisib | launched | PD-1, CTLA4, chemotherapy, targeted drug |
| CT-365 | I | monotherapy | |||
| duvelisib | launched | PD-1, chemotherapy, targeted drug | |||
| eganelisib | II | monotherapy | |||
| gedatolisib | I | chemotherapy | |||
| SF-112 | I | PD-1, targeted inhibitor | |||
| tenalisib | II | PD-1, targeted inhibitor | |||
| CD47/SIRPα pathway | 48 | 16 | AK-47 | II | monotherapy |
| ALX-148 | II | PD-1, chemotherapy | |||
| AO-176 | II | PD-1, chemotherapy | |||
| CC-90002 | I | targeted antibody | |||
| HX-009 | II | PD-1 | |||
| IBI-188 | II | chemotherapy | |||
| IBI-322 | I | monotherapy | |||
| IMC-002 | I | monotherapy | |||
| IMM-01 | I | monotherapy | |||
| IMM-0306 | I | monotherapy | |||
| lemzoparlimab | II | chemotherapy | |||
| magrolimab | III | PD-L1, chemotherapy, targeted drug | |||
| RRx-001 | III | chemotherapy, radiotherapy | |||
| TTI-622 | II | PD-1, chemotherapy | |||
| STING pathway | 39 | 17 | SNX-281 | I | PD-1 |
| BMS-986301 | I | PD-1, CTLA-4 | |||
| GSK-3745417 | I | PD-1 | |||
| E−7766 | I | monotherapy | |||
| SYNB-1891 | I | PD-L1 | |||
| TAK-676 | I | PD-1 | |||
| MK-2118 | I | PD-1 | |||
| ADU-S100 | II | PD-1, CTLA-4 | |||
| IMSA101 | II | PD-1, PD-L1 | |||
| CDK-002 | II | monotherapy | |||
| MK-1454 | II | PD-1 | |||
| NOX66 | II | PD-1, chemotherapy, radiotherapy | |||
| SB-11285 | II | PD-1 |